A novel series of thiazol-2-ylacetamide derivatives was synthesized via a multi-step protocol featuring a metal-free reductive C–C bond coupling as the key late-stage transformation. The synthetic route commenced with acylation of 5-acetylthiazole-2-amine to afford N-(5-acetylthiazol-2-yl)acetamide, which was converted to N-[5-(1-(2-tosylhydrazono)ethyl)thiazole-2-yl)acetamide. In the final step, a Barluenga-type metal-free reductive coupling between the resulting tosylhydrazone and a diverse set of boronic acids resulted in the successful synthesis of 10 target compounds thiazole-2-yl acetamides. This strategy offers broad substrate scope, good functional group tolerance, and metal-free conditions. The representative product, N-(5-isopropylthiazol-2-yl)acetamide, was further transformed via hydrolysis and N-acylation to afford three additional novel thiazole derivatives. Additionally, a control experiment afforded a racemic alcohol―N-[5-(1-hydroxyethyl)thiazol-2-yl]acetamide―which was resolved into 2 enantiomers by chiral HPLC. In total, 16 novel thiazole-containing target compounds were synthesized following optimization of each step. Future work will focus on the pharmacological evaluation of these new compounds.
No takes yet. Share an insight, caveat, or question.
Ayyagari et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: